ERBB2 and breast carcinoma: The development of anti-HER2 targeted therapies, including trastuzumab, lapatinib, pertuzumab, and trastuzumab emtansine (T-DM1), has markedly improved the treatment outcomes of HER2-positive breast cancer patients (3–7).